Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Opus Genetics, Inc.NASDAQ: IRD
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 38.7% from a year ago
Total assets stood at $66.79M at the end of Q1 FY2026, up 38.7% from a year earlier and up 32.9% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +38.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 50.24M USD
- Year-over-year change
- +36.3%
- 4-year CAGR
- +17.8%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.24M | +36.3% |
| FY2024 | 2024-12-31 | 36.86M | -31.7% |
| FY2023 | 2023-12-31 | 53.95M | +10.1% |
| FY2022 | 2022-12-31 | 48.99M | +87.9% |
| FY2021 | 2021-12-31 | 26.08M | — |
Total Assets vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 total assets of $66.79M is the 7th highest of the 10 companies compared; the peer median is $133.63M.
- Its year-over-year change of +38.7% is the 3rd highest of 10, against a peer median of -21.6%.
- Over three fiscal years its annual growth of +0.8% compares with a peer median of -18.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $272.13M | -21.6% | -15.3% | |
| Mar 2026 | $239.92M | -41.2% | -28.1% | |
| Mar 2026 | $200.43M | -15.6% | -25.0% | |
| Mar 2026 | $186.46M | -6.9% | -18.1% | |
| Mar 2026 | $133.63M | -34.6% | -14.5% | |
| Mar 2026 | $117.62M | -28.4% | -26.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $66.79M | +38.7% | +0.8% |
| Mar 2026 | $49.78M | -43.0% | -40.3% | |
| Mar 2026 | $36.14M | +53.8% | -1.4% | |
| Mar 2026 | $29.7M | +102.9% | +21.6% | |
| Peer median (excluding IRD) | $133.63M | -21.6% | -18.1% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.